Minoryx Therapeutics

Private

#Adrenoleukodystrophy (X-ALD)#Friedreich's Ataxia #CNS Rare Disease #PPAR Agonists

Minoryx Therapeutics is a clinical-stage biotechnology company developing differentiated therapies for X-linked adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. Its lead candidate, leriglitazone, is an oral, brain-penetrant PPAR-γ agonist for cerebral ALD and Friedreich's ataxia.

Company Info

Sector:Rare Disease Therapeutics

Headquarters:Mataró, Spain

Founded:2011

Website:www.minoryx.com/

CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa ↗

CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa.

Leadership Team

Careers & Job Openings

See all open roles

Multiple Departments

Spain - Barcelona

Apply Now →